Back to discover
Disease

Skin Diseases, Bacterial

Late-stage therapeutic developmentEmerging research
MeSHSkin Diseases, Bacterial
1
Publications
9
Clinical trials
1999
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia.

Research1999-11-01Clinical infectious diseases : an official publication of the Infectious Diseases Society of America

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

No activity recorded in this window. Try a wider timeframe.

Clinical trials

7 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
9
All trials
0
Active
4
Late-stage
6
Completed
Late-stage studies

A Double-Blind, Randomized Study to Evaluate the Safety of Either a Single 1200-mg Intravenous (IV) Dose of Orbactiv™ (Oritavancin) and Placebo or Two IV Doses of Orbactiv™ in Subjects Being Treated for Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

Phase 4 · Completed · The Medicines Company

A Multicenter, Randomized, Open-Label Comparison of the Safety And Efficacy of Tigecycline With That of Ampicillin-Sulbactam or Amoxicillin-Clavulanate to Treat Complicated Skin And Skin Structure Infections

Phase 4 · Completed · Wyeth is now a wholly owned subsidiary of Pfizer

A Multicenter, Randomized, Open-Label Study to Compare the Safety and Efficacy of i.v. And/Or Oral Levofloxacin With That of Ticarcillin/Clavulanate Alone or Followed by Amoxicillin/Clavulanate in the Treatment of Complicated Bacterial Skin and Skin Structure Infections

Phase 3 · Completed · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Phase 3, Randomized, Investigator-Blind, Multi-Center Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Linezolid in Complicated Skin and Skin Structure Infections (ASSIST-2)

Phase 3 · Completed · Arpida AG
Recently completed

A Phase 2, Multicenter, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Contezolid Acefosamil Compared to Linezolid Administered Intravenously and Orally to Adult Subjects With Acute Bacterial Skin and Skin Structure Infection

Phase 2 · Completed · MicuRx

A Double-Blind, Randomized Study to Evaluate the Safety of Either a Single 1200-mg Intravenous (IV) Dose of Orbactiv™ (Oritavancin) and Placebo or Two IV Doses of Orbactiv™ in Subjects Being Treated for Acute Bacterial Skin and Skin Structure Infection (ABSSSI)

Phase 4 · Completed · The Medicines Company

A Phase 2, Randomized, Double-blind, Multi-center Study to Evaluate the Safety and Efficacy of CEM-102 Compared to Linezolid in the Treatment of Acute Bacterial Skin Structure Infections

Phase 2 · Completed · Arrevus Inc.

A Multicenter, Randomized, Open-Label Comparison of the Safety And Efficacy of Tigecycline With That of Ampicillin-Sulbactam or Amoxicillin-Clavulanate to Treat Complicated Skin And Skin Structure Infections

Phase 4 · Completed · Wyeth is now a wholly owned subsidiary of Pfizer

Phase 3, Randomized, Investigator-Blind, Multi-Center Study to Evaluate Efficacy and Safety of Intravenous Iclaprim Versus Linezolid in Complicated Skin and Skin Structure Infections (ASSIST-2)

Phase 3 · Completed · Arpida AG

A Multicenter, Randomized, Open-Label Study to Compare the Safety and Efficacy of i.v. And/Or Oral Levofloxacin With That of Ticarcillin/Clavulanate Alone or Followed by Amoxicillin/Clavulanate in the Treatment of Complicated Bacterial Skin and Skin Structure Infections

Phase 3 · Completed · Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Research activity

1 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Most influential

Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 1999 · 1,761 cites
Recent publications

Involvement of Panton-Valentine leukocidin-producing Staphylococcus aureus in primary skin infections and pneumonia.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 1999 · 1,761 cites
Leading journals1
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America1
Leading researchers8
  • Bes M1
  • Etienne J1
  • Gauduchon V1
  • Godail-Gamot F1
  • Lina G1
  • Peter MO1
  • Piémont Y1
  • Vandenesch F1
Affiliations (unnormalised)1
  • Centre National de Référence de Toxémies Staphylococciques1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Skin diseases caused by bacteria.

Identifiers
MeSHSkin Diseases, Bacterial
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.